#China #Hong Kong #Peijia Medical #TaurusTrio #Aortic Regurgitation

Peijia Medical's Breakthrough in Aortic Regurgitation Treatment

In a remarkable advancement for cardiac care in China, Peijia Medical (9996.HK) has secured approval from the National Medical Products Administration (NMPA) for its TaurusTrio Transcatheter Aortic Valve (TAV) system. This innovative device addresses a critical gap in treatment options for patients suffering from symptomatic severe aortic regurgitation (AR), offering hope to those who previously faced limited choices.

A Pioneering Innovation

Launched on December 11, 2025, the TaurusTrio system is developed under a unique collaboration with JenaValve Technology, Inc. Leveraging the proprietary locator technology from JenaValve, the TaurusTrio establishes stable anchoring by engaging the native aortic leaflets, even in the absence of calcium, which is often absent in AR cases. This technological breakthrough allows for effective treatment through transfemoral access, making it a significant innovation in the field of interventional cardiology.

Clinical Success Evidence

The one-year clinical results from the TaurusTrio ALTER-AR study are promising, boasting a technical success rate of 99.1%. Notably, the system recorded a 0% all-cause mortality rate at 30 days and only 2.6% at one year, showcasing its safety and efficacy. Additionally, a substantial 91.7% of patients experienced improvement, regaining NYHA class I/II status within six months. These metrics reflect the system’s potential to enhance patients' quality of life significantly.

Addressing a Critical Need

Dr. Yi Zhang, Chairman and CEO of Peijia Medical, highlighted that many patients with severe AR have previously been ineligible for surgical interventions, accentuating the substantial need for ideal treatments. By utilizing JenaValve's advanced locator technology, Peijia Medical aims to proactively resolve the challenge of unstable anchoring, providing physicians with a critical tool while offering patients a long-awaited solution in AR treatment. This approval signifies a strategic breakthrough, symbolizing Peijia Medical's commitment to innovation and excellence in healthcare.

JenaValve's Support

John Kilcoyne, CEO of JenaValve, expressed his enthusiasm for the NMPA approval, which underscores the dedicated efforts over the years to introduce the TaurusTrio system in China. As the first transcatheter valve developed specifically for AR, TaurusTrio brings new hope to millions of underserved patients. Kilcoyne extended his gratitude towards the Peijia team for their partnership in this effort, reinforcing their mutual objective of advancing healthcare outcomes for AR patients.

Future Implications

The TaurusTrio is poised to transform the landscape of aortic regurgitation treatment in China, introducing a new era of precision, minimally invasive therapy. With its broader clinical adoption, this device promises extended survival and improved quality of life for patients navigating this challenging condition. Furthermore, it is a testament to the growing integration of global expertise within China's healthcare framework, aiming to bolster local innovations in medical technology.

About Peijia Medical

Founded in 2012 and headquartered in Suzhou, China, Peijia Medical is committed to advancing the interventional procedural medical device sector. The company’s portfolio includes multiple TAVR systems and a range of neurointerventional devices, catering to both structural heart and neurovascular diseases. With a focus on innovation and comprehensive treatment solutions, Peijia aims to solidify its position as a leading global medical device platform. For further information, visit Peijia Medical's website.